{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T07:51:34Z","timestamp":1758959494385},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T00:00:00Z","timestamp":1457913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radioimmunotherapy (<jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content>) after an induction phase with conventional chemoimmunotherapy became an attractive strategy of consolidation for patients with advanced follicular lymphoma: in particular, in many studies <jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content> was represented by yttrium\u201090\u2010ibritumomab tiuxetan (<jats:sup>90<\/jats:sup>Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content>). Independently by the different front\u2010line treatment, updates on the long\u2010term follow\u2010up of these studies are needed because the disease course of follicular lymphoma is characterised by multiple relapses and progressively shorter durations of response. We report updated long\u2010term efficacy and toxicity results of a multicenter phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study on sequential treatment with four cycles of fludarabine, mitoxantrone, and rituximab followed by <jats:sup>90<\/jats:sup>Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content> as front\u2010line therapy for untreated patients with intermediate\/high\u2010risk follicular lymphoma. With a median follow\u2010up of 84\u00a0months, only 19\/49 (38.8%) complete response patients relapsed, yielding an estimated long\u2010term disease\u2010free survival of 62.6%. The 7\u2010year overall survival was 72.7%. Four (7.3%) second acute myeloid leukemia occurred, with a median time following <jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content> of 42\u00a0months. A relevant patients' responsiveness to subsequent therapies occurred: approximately 65% of relapsed patients obtained a good clinical response after the second\u2010line treatment. These data represented the first evidence of a real role even in the long period of 90Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content> after a fludarabine\u2010containing regimen plus rituximab in the treatment of high\u2010risk follicular lymphoma.<\/jats:p>","DOI":"10.1002\/cam4.684","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T13:45:51Z","timestamp":1458308751000},"page":"1093-1097","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["90\u2010yttrium\u2010ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate\/high\u2010risk follicular lymphoma: updated long\u2010term results after a median follow\u2010up of 7\u00a0years"],"prefix":"10.1002","volume":"5","author":[{"given":"Beatrice","family":"Casadei","sequence":"first","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology \u201cLa Sapienza\u201d University  Roma Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Annechini","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology \u201cLa Sapienza\u201d University  Roma Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"De Renzo","sequence":"additional","affiliation":[{"name":"Division of Hematology \u201cFederico II\u201d University  Napoli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Gandolfi","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Quirini","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Tonialini","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Morigi","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non\u2010Hodgkin's lymphoma: the Non\u2010Hodgkin's Lymphoma Classification Project","volume":"89","author":"From The Non\u2010Hodgkin's Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4336"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70039-1"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr633"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.04.009"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.790544"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0529"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.044"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"3056a","DOI":"10.1182\/blood.V112.11.3056.3056","article-title":"R\u2010FND followed by radioimmunotherapy fpor high\u2010risk follicular lymphoma","volume":"112","author":"McLaughlin P.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr145"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_6_20_1","first-page":"3","article-title":"Bendamustine plus rituximab (B\u2010R) versus CHOP plus rituximab (CHOP\u2010R) as first\u2010line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study","volume":"30","author":"Rummel M. J.","year":"2012","journal-title":"ASCO Meet. Abs."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23540"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.07.013"},{"key":"e_1_2_6_23_1","first-page":"1","article-title":"Long\u2010term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma","volume":"11","author":"Reiss J.","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.113"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2882"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12695"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.004"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.684","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.684","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:01:36Z","timestamp":1696615296000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,14]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1002\/cam4.684"],"URL":"https:\/\/doi.org\/10.1002\/cam4.684","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,14]]},"assertion":[{"value":"2015-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}